McGovern Medical School at University of Texas Health Science Center, Houston, TX.
Children's Memorial Hermann Hospital, Houston, TX.
Neoreviews. 2023 Jun 1;24(6):e370-e376. doi: 10.1542/neo.24-6-e370.
Anemia of prematurity affects the majority of preterm infants, particularly extremely low birthweight infants. Anemia of prematurity arises from both innate and iatrogenic causes and results in more than 80% of extremely preterm infants receiving red blood cell transfusions during the first month after birth. Multiple randomized controlled trials were conducted to evaluate the effect of using lower versus higher transfusion thresholds based on hemoglobin levels. These trials showed no difference in the primary outcome of neurodevelopmental impairment at 2 years of age between lower and higher thresholds. However, some uncertainties about transfusion thresholds remain. This review elaborates the following: 1) the etiology, prevention, and treatment of anemia of prematurity with a focus on red blood cell transfusions, 2) the history of randomized controlled trials on the treatment of anemia of prematurity, and 3) limitations of the evidence and remaining questions about thresholds for red blood cell transfusions in preterm infants.
早产儿贫血影响大多数早产儿,尤其是极低出生体重儿。早产儿贫血由先天和医源性原因引起,超过 80%的极早产儿在出生后第一个月接受红细胞输血。多项随机对照试验评估了基于血红蛋白水平使用较低与较高输血阈值的效果。这些试验表明,较低和较高阈值之间在 2 岁时神经发育障碍的主要结局没有差异。然而,输血阈值仍存在一些不确定性。本综述详细阐述了以下内容:1)早产儿贫血的病因、预防和治疗,重点是红细胞输血,2)早产儿贫血治疗的随机对照试验历史,3)证据的局限性和早产儿红细胞输血阈值的剩余问题。